SVRA

Savara Inc. [SVRA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

SVRA Stock Summary

In the News

SVRA Financial details

Company Rating
-
Market Cap
700.41M
Income
-52.38M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
37
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-14.85
Forward P/E
-
PEG
-5.44
P/S
-
P/B
4.8
P/C
-
P/FCF
-13.05
Quick Ratio
18.88
Current Ratio
18.98
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.32
EPS next Y
-
EPS next Q
-
EPS this Y
32%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-10.5%
-
-
-
-
SMA20
-2.81%
SMA50
-20.63%
SMA100
-37.19%
Inst Own
-
Inst Trans
-
ROA
-26%
ROE
-43%
ROC
-0.31%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.69-5.7
52W High
-46.2%
52W Low
+169%
RSI
40.81
Rel Volume
0.88
Avg Volume
791.03K
Volume
692.86K
Perf Week
-2.18%
Perf Month
-11.8%
Perf Quarter
-36.1%
Perf Half Y
-39.96%
-
-
-
-
Beta
0.697
-
-
Volatility
0.06%, 0.1%
Prev Close
0%
Price
2.69
Change
-3.93%

Something similar

Top by Market Cap
EMBASSY.NS
FB2A.DE
META
VOO
DHR-PB
Same Sector
ALCLS.PA
KRTX
USNU
APLI.TO
ACIU
Same Price Range
JPASSOCIAT.NS
002218.SZ
LEVIX
0737.HK
VIJIFIN.NS
Similar Market Cap
HRT
THL.NZ
ABST.TO
0505.HK
HFG.L

Company Profile

Healthcare Biotechnology
  • Volume Average 791.03K
  • Market Capitalization 700.41M
  • Employee 37
  • CEO Mr. Matthew Pauls J.D., M.B.A.
  • Headquarters Austin,TX,US
  • IPO Date 2017-04-28
  • Website https://www.savarapharma.com

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.